Ironwood Pharmaceuticals Initiates Clinical Studies of Soluble Guanylate Cyclase Stimulators IW-1973 and IW-1701

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. ACN
3. NVDA
4. USO
5. GOOGL
6. APGE
7. MU
8. HOOD
9. DFTX
10. MSFT

Go back to Ironwood Pharmaceuticals Initiates Clinical Studies of Soluble Guanylate Cyclase Stimulators IW-1973 and IW-1701

Ironwood Pharma's (IRWD) Linzess Sales Missed Estimates; Leerink Partners Reiterates Market Perform

November 4, 2015 9:30 AM EST

Leerink Partners maintained a Market Perform rating and $12.00 price target on Ironwood Pharmaceuticals (NASDAQ: IRWD), following the company's 3Q earnings report. IRWD reported 3Q Linzess sales of ~$117m coming in modestly below Leerink's estimate of ~$121m.

Analyst Jason Gerberry commented, "IRWD reported 3Q Linzess sales of ~$117m coming in modestly... More